Biomerieux SA (BIM) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Biomerieux SA (BIM) has a cash flow conversion efficiency ratio of 0.115x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€470.80 Million ≈ $550.41 Million USD) by net assets (€4.11 Billion ≈ $4.80 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See BIM defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Biomerieux SA - Cash Flow Conversion Efficiency Trend (2005–2025)
This chart illustrates how Biomerieux SA's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Biomerieux SA Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Biomerieux SA ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
UNICHARM CORP. SP.ADR 1
F:UN41
|
0.047x |
|
Primerica Inc
NYSE:PRI
|
0.062x |
|
Orion Oyj B
HE:ORNBV
|
0.086x |
|
DISCOVERY LTD(UNSP.ADR)/3
F:D3H0
|
N/A |
|
Alpha Services and Holdings S.A.
AT:ALPHA
|
0.143x |
|
Chang Hwa Commercial Bank Ltd
TW:2801
|
0.031x |
|
Hunan Yuneng New Energy Battery Material Co. Ltd. A
SHE:301358
|
N/A |
|
Tongwei Co Ltd
SHG:600438
|
0.101x |
Annual Cash Flow Conversion Efficiency for Biomerieux SA (2005–2025)
The table below shows the annual cash flow conversion efficiency of Biomerieux SA from 2005 to 2025. For the full company profile with market capitalisation and key ratios, see Biomerieux SA stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €4.11 Billion ≈ $4.80 Billion |
€788.30 Million ≈ $921.61 Million |
0.192x | +21.15% |
| 2024-12-31 | €4.21 Billion ≈ $4.92 Billion |
€667.30 Million ≈ $780.14 Million |
0.158x | +33.50% |
| 2023-12-31 | €3.75 Billion ≈ $4.39 Billion |
€445.40 Million ≈ $520.72 Million |
0.119x | -8.98% |
| 2022-12-31 | €3.64 Billion ≈ $4.26 Billion |
€475.10 Million ≈ $555.44 Million |
0.130x | -49.13% |
| 2021-12-31 | €3.16 Billion ≈ $3.70 Billion |
€811.10 Million ≈ $948.26 Million |
0.256x | +9.16% |
| 2020-12-31 | €2.48 Billion ≈ $2.90 Billion |
€582.80 Million ≈ $681.35 Million |
0.235x | +29.82% |
| 2019-12-31 | €2.25 Billion ≈ $2.64 Billion |
€407.90 Million ≈ $476.88 Million |
0.181x | -9.40% |
| 2018-12-31 | €2.00 Billion ≈ $2.34 Billion |
€399.80 Million ≈ $467.41 Million |
0.200x | +1.62% |
| 2017-12-31 | €1.74 Billion ≈ $2.03 Billion |
€341.30 Million ≈ $399.02 Million |
0.197x | -5.06% |
| 2016-12-31 | €1.62 Billion ≈ $1.90 Billion |
€335.60 Million ≈ $392.35 Million |
0.207x | +0.33% |
| 2015-12-31 | €1.50 Billion ≈ $1.76 Billion |
€310.00 Million ≈ $362.42 Million |
0.206x | -3.96% |
| 2014-12-31 | €1.39 Billion ≈ $1.62 Billion |
€298.30 Million ≈ $348.74 Million |
0.215x | +13.19% |
| 2013-12-31 | €1.27 Billion ≈ $1.48 Billion |
€240.50 Million ≈ $281.17 Million |
0.190x | -11.89% |
| 2012-12-31 | €1.20 Billion ≈ $1.40 Billion |
€258.50 Million ≈ $302.21 Million |
0.215x | +9.72% |
| 2011-12-31 | €1.10 Billion ≈ $1.29 Billion |
€216.60 Million ≈ $253.23 Million |
0.196x | -3.71% |
| 2010-12-31 | €976.10 Million ≈ $1.14 Billion |
€199.00 Million ≈ $232.65 Million |
0.204x | -12.83% |
| 2009-12-31 | €806.40 Million ≈ $942.77 Million |
€188.60 Million ≈ $220.49 Million |
0.234x | -18.64% |
| 2008-12-31 | €688.40 Million ≈ $804.81 Million |
€197.90 Million ≈ $231.37 Million |
0.287x | -8.39% |
| 2007-12-31 | €601.30 Million ≈ $702.98 Million |
€188.70 Million ≈ $220.61 Million |
0.314x | +40.41% |
| 2006-12-31 | €557.50 Million ≈ $651.78 Million |
€124.60 Million ≈ $145.67 Million |
0.223x | -32.27% |
| 2005-12-31 | €498.50 Million ≈ $582.80 Million |
€164.50 Million ≈ $192.32 Million |
0.330x | -- |
About Biomerieux SA
bioMérieux S.A. develops, manufactures, and markets in vitro diagnostic solutions for infectious diseases in France, Europe, Africa, the Middle East, North and South America, the Asia Pacific, and internationally. It operates through Clinical Applications and Industrial Applications segments. The company offers CHROMID RANGE, a chromogen culture media; air, surface, and water monitoring systems; … Read more